How to Prepare Performance Verification Documentation for Overseas Registration of Imaging Equipment

Key Summary

A professional guide for medical device manufacturers on preparing performance verification documentation for overseas registration of imaging equipment. It covers regulatory classification, registration pathway, reusable data, gap analysis, common pitfalls, and strategic recommendations from AIMEILI for multi-country

Key Answer: For imaging equipment, performance verification documentation for overseas registration should be prepared by first confirming the product's regulatory classification in the target market, then determining the risk class and registration pathway, and finally assessing which existing NMPA, CE, FDA, ISO 13485, or MDSAP data can be reused. The documentation must cover performance testing, software verification, risk management, clinical evaluation, labeling, local agent arrangements, and post-market maintenance, with attention to local standards, laboratory qualifications, and language requirements.

Published: August 13, 2026 21:38 | Updated: August 13, 2026 21:38

Key Summary

Performance verification documentation is the most common source of deficiency requests in overseas registration of imaging equipment. Manufacturers should not simply submit domestic (NMPA) test reports directly. Instead, they should first determine whether the target country regulates the product as a medical device, then confirm the risk class, registration pathway, and the entity responsible for the application.

Different countries have varying requirements for test standards, data sources, laboratory qualifications, and language. A systematic assessment should be conducted to evaluate whether existing NMPA, CE, FDA, ISO 13485, or MDSAP documentation can be reused, and to fill gaps in performance verification, software verification, risk management, clinical evaluation, labeling, local agent representation, and post-market maintenance. Common risks include outdated standards, incomplete raw data, missing software lifecycle documents, submission in the wrong language, and lack of a valid local agent, which can lead to delays and deficiency letters.

Enterprises should establish a core technical documentation master file early, perform country-specific gap analyses and localization conversions, and control certificates, handle changes, and manage renewals through a reliable local agent. For Chinese medical device manufacturers, a prudent approach is to first conduct product classification and documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market data can be reused. Registration in target markets typically affects technical documentation, authorized representation, importer cooperation, labeling language, quality system evidence, and subsequent change management. If the project is driven only by “which documents to submit,” issues such as model coverage, evidence chain consistency, labeling claims, and certificate control may result in deficiencies or rework. AIMEILI recommends treating this as part of a GHWP member country and multi-country market access strategy, using a reusable core technical document set to support localization in different markets rather than recreating documentation from scratch for each country.

Applicable Scenarios and Core Issues

Imaging equipment covers a broad range, from X-ray systems, ultrasound diagnostic devices, CT, MRI, to endoscopic camera systems, all of which fall under medical device regulation. Enterprises planning to enter GHWP member countries or other overseas markets face a common question: how to prepare performance verification documentation that will be accepted by local regulatory authorities.

“Performance verification” here is not just a test report; it is a multi-layered evidence chain covering product technical specifications, performance indicators, test methods, raw test records, software documentation, risk management, and clinical evaluation. Different countries have different regulatory requirements—some accept reports from the country of origin, others require local testing, and some mandate specific technical documentation formats.

The most overlooked point is that performance verification for overseas registration is not just a technical issue but a regulatory decision. One must first determine the product's regulatory classification in the target country, then the risk class and registration pathway, and only then the specific documentation set. This article applies to the following scenarios: planning registration of imaging equipment in Southeast Asia, the Middle East, Latin America, Africa, or other regions; having existing NMPA registration or CE certificates and wishing to reuse data; being in the early design and development phase and needing to plan multi-country registration strategy; and having already submitted registration and received a deficiency letter, requiring reorganization of performance verification documentation.

Registration Decision Logic

Step 1: Confirm Regulatory Classification

Most countries regulate imaging devices as medical devices, but some products may be classified as radiation equipment, electronic devices, or standalone software, leading to a completely different application pathway. The first step is to verify whether the product falls under the scope of the target country's medical device regulation.

Step 2: Determine Risk Class and Registration Pathway

Imaging equipment is usually classified as Class II or III medical devices. Some countries use classification rules based on GHTF/IMDRF guidelines. Enterprises need to map the product's intended use, invasiveness, energy source, and other characteristics against the local classification system.

Step 3: Confirm the Applicant Entity

Overseas registration typically requires a local registrant, importer, or local agent to submit the application. Enterprises must identify the local agent or authorized representative and clearly define their roles and responsibilities.

Step 4: Assess Reusability of Existing Documentation

If the product already holds an NMPA registration certificate, CE certificate, or FDA 510(k) clearance, the corresponding test reports, quality management system certificates, and technical documentation summaries should be reviewed to determine which data can be directly used and what needs to be supplemented.

Step 5: Establish the Target Country Technical Document List

Many countries adopt or reference IMDRF/RPS formats and also consider regional harmonized documents from ASEAN, GCC, and other organizations. Enterprises should organize modules according to the target country's format and mark the source and validity of each piece of evidence.

Step 6: Perform a Gap Analysis

Compare existing documentation with the target country's requirements to identify gaps in performance verification, software verification, risk management, labeling, clinical evaluation, and other areas. Then create a plan for supplementary testing or documentation.

Documentation and Evidence

The core of performance verification documentation is to prove that the product meets specified performance and safety requirements under intended use conditions. The following technical documents are typically required for imaging equipment:

Product Technical Requirements or Specification: Specify device model, main functions, performance indicators, and referenced standards. For imaging equipment, performance indicators generally include image resolution, contrast, noise, spatial accuracy, dose accuracy, and imaging time. These must be consistent with the intended use and product claims.
Performance Test Reports: Reports should come from laboratories accredited to ISO 17025 or equivalent local requirements. Reports must contain test methods, sample information, test conditions, and raw data. For electrical safety, electromagnetic compatibility, biocompatibility, radiation safety, environmental testing, and other items, confirm which version of the standard is accepted by the target country.
Software Verification Documentation: Modern imaging equipment often includes software. Software lifecycle documentation should be provided in accordance with IEC 62304 or an equivalent standard, including software requirements, architecture design, verification testing, vulnerability assessment, and safety statements. Many deficiency letters are issued due to missing software documentation.
Risk Management Report: Usually following ISO 14971, it includes risk analysis, risk evaluation, risk control measures, and residual risk assessment. For imaging equipment, risks associated with radiation dose, patient injury, and misdiagnosis should be addressed, and the report should demonstrate a link to performance verification data.
Clinical Evaluation or Clinical Evidence: Not all imaging equipment requires clinical trials, but a rational justification based on intended use, technical characteristics, and existing literature is necessary. Some countries may require clinical data, equivalence comparisons, or literature summaries.
Labeling, Instructions for Use, and Packaging Information: Must be in the target country's language. The instructions for use must include indications, contraindications, warnings, operating steps, and maintenance schedules. Symbols on labels must comply with local regulations or harmonized standards.
Quality Management System Certificate: Such as ISO 13485 or MDSAP certificate, usually submitted as part of the technical documentation or during quality system audits. The manufacturer's name and address on the certificate must be consistent with the registration application.
Local Agent and Authorized Representative Documentation: Includes agency agreement, power of attorney, and the agent's qualification proof. Some countries require the agent to be a locally registered company responsible for post-market communication and adverse event reporting.
Post-Market Surveillance Plan and Adverse Event Reporting Procedures: The registration file should include arrangements for after-sales surveillance in the target country, including complaint handling, safety notices, annual updates, or renewals.

Common Mistakes

Directly submitting NMPA test reports without checking the target country's standard version and applicable differences, leading to non-compliance with local requirements.
Omitting software documentation, treating software as an accessory to hardware, and lacking software requirements, verification records, and risk management documents.
Providing incomplete raw data from test reports, such as only summary pages, and being required to submit curves, waveforms, images, or original records.
Risk management reports not linked to performance indicators, and risk control measures lacking corresponding verification evidence.
Labels and instructions for use not translated into the target country's language, or translated inaccurately, causing inconsistencies with the registered content.
Ignoring local laboratory, GCP, or GLP requirements, and using data sources that are not recognized.
Failing to appoint a local agent or authorized representative, making it impossible for the regulatory authority to communicate, and the application being rejected.
Preparing static registration documents only, without preparing verification data needed for post-market changes and re-registration, leading to missing documents when changes occur.

Enterprise Preparation Checklist

List target countries and confirm the regulatory classification, registration pathway, applicant entity, and fees for each.
Establish an international regulatory affairs team or engage an experienced consultancy for gap analysis and submission strategy.
Create a product technical documentation master file including performance indicators, test reports, software documentation, risk management, and clinical evaluation.
Check the target country's standards list and confirm that the latest versions are used, assessing differences.
Select testing laboratories, confirming their qualifications, capability scope, and data acceptability.
Complete software lifecycle documentation, especially software requirements specification and verification test records.
Complete localization translation and regulatory compliance review of labels and instructions for use.
Select a local agent or authorized representative, sign the authorization letter, and clarify duties.
Develop a post-market surveillance program, including complaint handling, adverse event reporting, and annual updates.
Set a project timeline, reserving time for any supplemental performance testing, translation, notarization, and post-submission response.

AIMEILI Regulatory Interpretation and Business Impact

The most common misunderstanding is equating performance verification documentation with a “test report.” In reality, overseas regulators place greater emphasis on the completeness and traceability of the evidence chain. The test report is only the result; the underlying standard selection, test methods, raw data, software documents, and risk management are where deficiencies are most likely to be raised.

Enterprises should perform a target country gap analysis early in the project, not wait until after submission. AIMEILI recommends that as soon as an overseas market entry plan is set, companies should evaluate the coverage of existing NMPA, CE, and FDA documentation and use the gap analysis results as input for product changes or new project design. This allows verification gaps to be filled at lower cost rather than through urgent supplementary testing during the registration process.

Which documents can be reused? Basic performance tests, electrical safety, electromagnetic compatibility, biocompatibility, and quality management system certificates can be reused in most countries, provided that standard versions and test validity periods are checked. What must be localized? Standard differences, language translation, local acceptance of clinical evaluation, agent documents, complaint contact channels, and regulatory requirements.

Local agents, certificate control, changes, and renewals are the areas where overseas registration is most prone to problems. Enterprises must define the agent's responsibilities through a contract and ensure that certificates are controlled directly by the manufacturer or regulatory authority, not fully delegated to an intermediary. Any significant technical change after approval requires notification to the local authority or re-registration, and original performance data must be readily retrievable.

For multi-country registration, avoid duplicate preparation and deficiency risks. AIMEILI recommends a structure of “core technical documentation master file + country-specific difference list.” For each country, only prepare the difference module rather than creating a separate set of documents for each country. This ensures data consistency, reduces maintenance costs, and facilitates future changes and renewals.

Common Follow-up Questions

Is performance verification for imaging equipment required to be performed locally in the target country?

Not necessarily. Most GHWP member countries accept test reports from laboratories in the country of origin or third countries, provided the laboratory has the appropriate qualifications and the report meets local requirements. Some countries may require confirmation testing of image quality, dose, or other optical/radiation parameters, or may require review by an importing-country testing institution. Enterprises should confirm data acceptability with the local agent or regulatory authority before registration.

Can an existing CE certificate be directly used for registration in Southeast Asia or the Middle East?

CE certificates and technical reports are valuable references but cannot directly replace the target country's registration documentation. Southeast Asian and Middle Eastern countries generally reference international standards but have their own registration formats, language, and agent requirements. For example, Malaysia requires local MDA approval, and the UAE requires a local authorized representative and uses a different document numbering system from CE. Enterprises should reorganize the core technical documentation and convert it to the target country's format.

Does a software update count as a change in overseas registration? What are the principles for supplementary testing?

Yes. Most regulatory authorities require manufacturers to assess whether a software update that affects safety or performance warrants re-registration or a change application. The principle for supplementary testing is: if the imaging processing algorithm, user interface, or communication functions affect the intended use, performance verification and software regression testing are required. If it is only an internal bug fix that does not affect safety, records should still be kept and reported as required. Enterprises should set up a software change control procedure that includes a regulatory impact assessment.

Need a registration pathway assessment?

Send product type, intended use, target countries and existing certificates. AIMEILI can help evaluate registration pathway, documentation gaps and compliance risks.

Contact AIMEILI